SB-699551 free base
Based on 1 publication(s) in Google Scholar
SB-699551 free base is a selective and brain penetrant 5-HT5A receptor antagonist with a pKi of 8.2 nM. SB-699551 free base shows high selectivity over most other 5-HT receptor subtypes, dopamine receptors, and α1B adrenoceptor. SB-699551 free base disrupts Gαi/o-coupled and PI3K/AKT/mTOR signaling pathways, alters CREB, ATF1, AKT, PRAS40, S6K, and FOXO1 phosphorylation in breast tumor cells. SB-699551 free base can be used for the research of anxiety, breast cancer, and Alzheimer's disease.
For research use only. We do not sell to patients.
- CAS No.: 791789-61-2
- Formula: C34H45N3O
- Molecular Weight:511.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) SB-699551 free base
MoreAll 5-HT Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
5-HT5A Receptor 8.2 (pKi) |
5-HT1A Receptor 6.3 (pKi) |
5-HT1B Receptor 6.5 (pKi) |
5-HT1D Receptor 6.4 (pKi) |
5-HT2A Receptor 6.1 (pKi) |
5-HT2B Receptor 6.0 (pKi) |
5-HT2C Receptor 6.4 (pKi) |
5-HT6 Receptor 5.4 (pKi) |
5-HT7 Receptor 5.4 (pKi) |
In Vitro
SB-699551 free base potently binds to human 5-HT5A receptors expressed in CHO cells with a pKi of 8.2 and exhibits ≥100-fold selectivity against most other 5-HT receptor subtypes[1].
SB-699551 free base (1 μM) acts as a competitive antagonist at human 5-HT5A receptors expressed in HEK 293 cells, with an apparent pKB of 8.0[1].
SB-699551 free base (72 h) inhibits tumorsphere formation and cell viability in HCC1954 and MCF-7 human breast tumor cell lines with IC50 values ranging from 0.2 to 0.3 μM[3].
SB-699551 free base inhibits tumorsphere formation in PDX-derived human breast tumor cell lines (PDX 81, PDX 18, PDX 12) with IC50 values ranging from 470 nM to 775 nM, independent of subtype[3].
SB-699551 (4 μM, 30 min; 4 μM, 5-60 min; 3-5 μM, 24 h) modulates signaling via the Gαi/o pathway and the PI3K/AKT/mTOR axis in MCF-7 and MDA-MB-157 human breast tumor cell lines, with increased CREB phosphorylation and reduced phosphorylation of AKT and downstream targets[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
SB-699551 (3-60 mg/kg; i.p.; once) free base shows anxiolytic-like effects in the foot-shock-induced USV model with an ED50 of 25.4 mg/kg[2].
SB-699551-A (3-30 mg/kg; i.p.; three times: 23.5, 5, and 1 h before test) free base does not exhibit antidepressant-like effects in the forced swim test[2].
SB-699551 (25 mg/kg; i.p.; 5 days a week; 3 weeks) free base reduces human breast tumor xenograft growth in NOD/SCID mice[3].
SB-699551 (0.1-3.0 mg/kg; s.c.; single injection post-first autoshaping session) free base impairs short-term memory at 0.3 mg/kg and long-term memory at 0.3, 1.0, and 3.0 mg/kg in male Wistar rats in an autoshaping associative learning task[4].
SB-699551 (0.3-3.0 mg/kg; s.c.) free base prevents forgetting induced by a 216-hour interruption of autoshaping training in rats[5].
SB-699551 (0.3 mg/kg; s.c.) free base alone induces amnesia-like effects in rats, with co-administration with Dizocilpine (HY-15084B) reversing these effects in 48-hour long-term memory and co-administration with Scopolamine (HY-N0296) reversing effects in 1.5-hour short-term and 24- and 48-hour long-term memory[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hannover Wistar (male, 240-290 g and 160-210 g)[2]
-
Dosage:3, 10, 30 mg/kg
-
Administration:i.p.
-
Result:Showed a dose-dependent tendency to decrease the number of square entries; dose-dependently decreased the number of rearings and groomings, with significant effects at 10 and 30 mg/kg doses, respectively; did not induce writhing behavior.
-
Animal Model:Hannover Wistar (male, 225-360 g, 8-12 animals/group)[2]
-
Dosage:3, 10, 30, 60 mg/kg
-
Administration:i.p.
-
Result:Dose-dependently decreased ultrasonic vocalization, with a significant effect at 30 mg/kg and an ED50 value of 25.4 mg/kg.
-
Animal Model:NOD/SCID (female, 6-8-week old) injected with HCC1954 cells[3]
-
Dosage:25 mg/kg
-
Administration:i.p.; 5 days a week; 3 weeks
-
Result:Reduced xenograft growth rate compared to vehicle; Induced large fibrotic areas with reduced tumor cell density and a subtle increase in TUNEL-positive cells in xenografts.
-
Animal Model:Wistar (male, 12 weeks-old, body weight reduced to 85% of ad libitum weight)[4]
-
Dosage:0.1, 0.3, 1.0, 3.0 mg/kg
-
Administration:s.c.; single injection post-first autoshaping session
-
Result:Decreased conditioned responses (CR%) during both short-term memory (1.5 h) and long-term memory (24 h) at 0.3 mg/kg; decreased CR% during long-term memory (24 h) at 1.0 and 3.0 mg/kg relative to vehicle controls (all effects significant per Tukey test); showed no significant effect at 0.1 mg/kg.
-
Animal Model:Wistar rats (adult male)[5]
-
Dosage:0.3, 3.0 mg/kg
-
Administration:s.c.
-
Result:Produced a significant anti-forgetting effect (114% of control-saline group values) at 0.3 mg/kg; produced a slight anti-forgetting effect (82% of control-saline group values) at 3.0 mg/kg following the 216-hour interruption period.
-
Animal Model:Wistar rats (adult male)[5]
-
Dosage:0.3 mg/kg
-
Administration:s.c.
-
Result:Induced amnesia-like effects with significant decrements in conditioned responses (CR) at 1.5 hours, 24 hours, and 48 hours; co-administration with dizocilpine reversed these effects in 48-hour long-term memory; co-administration with scopolamine reversed effects in 1.5-hour short-term and 24- and 48-hour long-term memory.
Chemical Information
-
CAS No. 791789-61-2
-
Molecular Weight 511.74
-
Formula C34H45N3O
-
SMILES
O=C(N(CCN(C)C)CC1=CC=C(C2=CC=C(CNCCC3=CC=CC=C3)C=C2)C=C1)CCC4CCCC4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer Ther
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. [Abstract]2024 Oct 1;23(10):1404-1417. PMID: 38894678
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
[1]. Corbett DF, et al. Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry. Bioorg Med Chem Lett. 2005;15(18):4014-4018. [Content Brief]
[2]. Kassai F, et al. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression. Behav Pharmacol. 2012;23(4):397-406. [Content Brief]
[3]. Gwynne WD, et al. Antagonists of the serotonin receptor 5A target human breast tumor initiating cells. BMC Cancer. 2020;20(1):724. Published 2020 Aug 5. [Content Brief]
[4]. Gonzalez R, et al. Role of 5-HT5A receptors in the consolidation of memory. Behav Brain Res. 2013 Sep 1;252:246-51. [Content Brief]
[5]. Aparicio-Nava L, et al. Effects of 5-HT5A receptor blockade on amnesia or forgetting. Behav Brain Res. 2019;357-358:98-103. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)